Cargando…
Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus
INTRODUCTION: Lichen planus is a chronic disease with often disappointing and less than optimal treatment options. Apremilast modulates inflammatory signalling pathways which play a central role in the pathogenesis of lichen planus, thus making it useful in the management of such patients. MATERIALS...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9725926/ https://www.ncbi.nlm.nih.gov/pubmed/36483748 http://dx.doi.org/10.2147/CCID.S390591 |
_version_ | 1784844671691784192 |
---|---|
author | Viswanath, Vishalakshi Joshi, Pradnya Dhakne, Mayuri Dhoot, Dhiraj Mahadkar, Namrata Barkate, Hanmant |
author_facet | Viswanath, Vishalakshi Joshi, Pradnya Dhakne, Mayuri Dhoot, Dhiraj Mahadkar, Namrata Barkate, Hanmant |
author_sort | Viswanath, Vishalakshi |
collection | PubMed |
description | INTRODUCTION: Lichen planus is a chronic disease with often disappointing and less than optimal treatment options. Apremilast modulates inflammatory signalling pathways which play a central role in the pathogenesis of lichen planus, thus making it useful in the management of such patients. MATERIALS AND METHODS: The present study was an investigator-initiated, single-centre, non-randomized, open-label, pilot study of the efficacy and safety of Apremilast in the treatment of lichen planus. All the patients were prescribed Apremilast 30mg, twice daily, for 12 weeks. Patients were evaluated for improvement in their lesions, based on the physician’s global assessment (PGA), subject global assessment (SGA), and target area lesion symptom score (TALSS). RESULTS: A total of 34 patients were included in the study; 26 patients completed the study duration and were considered for the final analysis. After 12 weeks, 34.61% (n = 9/26) patients showed 2 or more grade improvement in their disease as per PGA. About 42.30% (n = 11/26) patients achieved more than 50% improvement in their lesions based on the subject global assessment of their disease. There was a significant improvement in TALSS during the study period (p < 0.0001). Only 23.07% (n = 6/26) patients developed one or more adverse events because of Apremilast with headache being the commonest side effect. CONCLUSION: The results obtained in our study justify that Apremilast is efficacious and safe in the management of patients with lichen planus. Based on these results, Apremilast can be considered as a promising alternative treatment option in patients with lichen planus. |
format | Online Article Text |
id | pubmed-9725926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-97259262022-12-07 Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus Viswanath, Vishalakshi Joshi, Pradnya Dhakne, Mayuri Dhoot, Dhiraj Mahadkar, Namrata Barkate, Hanmant Clin Cosmet Investig Dermatol Original Research INTRODUCTION: Lichen planus is a chronic disease with often disappointing and less than optimal treatment options. Apremilast modulates inflammatory signalling pathways which play a central role in the pathogenesis of lichen planus, thus making it useful in the management of such patients. MATERIALS AND METHODS: The present study was an investigator-initiated, single-centre, non-randomized, open-label, pilot study of the efficacy and safety of Apremilast in the treatment of lichen planus. All the patients were prescribed Apremilast 30mg, twice daily, for 12 weeks. Patients were evaluated for improvement in their lesions, based on the physician’s global assessment (PGA), subject global assessment (SGA), and target area lesion symptom score (TALSS). RESULTS: A total of 34 patients were included in the study; 26 patients completed the study duration and were considered for the final analysis. After 12 weeks, 34.61% (n = 9/26) patients showed 2 or more grade improvement in their disease as per PGA. About 42.30% (n = 11/26) patients achieved more than 50% improvement in their lesions based on the subject global assessment of their disease. There was a significant improvement in TALSS during the study period (p < 0.0001). Only 23.07% (n = 6/26) patients developed one or more adverse events because of Apremilast with headache being the commonest side effect. CONCLUSION: The results obtained in our study justify that Apremilast is efficacious and safe in the management of patients with lichen planus. Based on these results, Apremilast can be considered as a promising alternative treatment option in patients with lichen planus. Dove 2022-12-02 /pmc/articles/PMC9725926/ /pubmed/36483748 http://dx.doi.org/10.2147/CCID.S390591 Text en © 2022 Viswanath et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Viswanath, Vishalakshi Joshi, Pradnya Dhakne, Mayuri Dhoot, Dhiraj Mahadkar, Namrata Barkate, Hanmant Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus |
title | Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus |
title_full | Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus |
title_fullStr | Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus |
title_full_unstemmed | Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus |
title_short | Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus |
title_sort | evaluation of the efficacy and safety of apremilast in the management of lichen planus |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9725926/ https://www.ncbi.nlm.nih.gov/pubmed/36483748 http://dx.doi.org/10.2147/CCID.S390591 |
work_keys_str_mv | AT viswanathvishalakshi evaluationoftheefficacyandsafetyofapremilastinthemanagementoflichenplanus AT joshipradnya evaluationoftheefficacyandsafetyofapremilastinthemanagementoflichenplanus AT dhaknemayuri evaluationoftheefficacyandsafetyofapremilastinthemanagementoflichenplanus AT dhootdhiraj evaluationoftheefficacyandsafetyofapremilastinthemanagementoflichenplanus AT mahadkarnamrata evaluationoftheefficacyandsafetyofapremilastinthemanagementoflichenplanus AT barkatehanmant evaluationoftheefficacyandsafetyofapremilastinthemanagementoflichenplanus |